GPR41 Agonism Curbs Endotoxemic Inflammation via Autophagy-Dependent NF-κB Suppression
- GPR41/FFAR3, a short-chain-fatty-acid-sensing GPCR, was tested as a target for dampening gut-derived endotoxemia in a macrophage model of endotoxin stress.
- The selective agonist AR420626 activated GPR41 and blunted downstream pro-inflammatory signaling, cutting output of nitric oxide, IL-6, MCP-1, and iNOS.
- This anti-inflammatory effect tracked to suppression of NF-κB signaling, the central pathway driving those mediators.
- Agonist treatment also boosted autophagic flux, marked by increased LC3-I-to-LC3-II conversion.
- Blocking autophagy pharmacologically erased AR420626's protective effect, indicating autophagy induction is mechanistically required rather than incidental to the anti-inflammatory action.
- Findings position GPR41 as a druggable node linking gut microbial metabolite sensing to control of systemic inflammation in metabolic endotoxemia.
AR420626 is doing its job as a chemical probe here, not auditioning as a drug — worth keeping that line bright. The autophagy-blockade rescue experiment is the real anchor: losing the phenotype when you knock out autophagy is exactly the epistasis data that justifies chasing GPR41 rather than filing it under "yet another anti-inflammatory hit." Selectivity is my first question mark — GPR41 sits right next to GPR43/FFAR2 in the SCFA-sensing GPCR family, sharing pocket architecture, so I'd want counter-screens before trusting any binding-mode hypothesis. Tractability-wise, class A GPCRs are historically good chemical space, but SCFA-mimetic ligands trend small and polar — solid fragment-to-lead starting points, not obviously oral-bioavailable as-is. Early hit-validation signal, not a lead series yet.